{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086085","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.445202+00:00","generated_at":"2026-05-31T12:21:47.022081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bicycle Therapeutics Q2 net loss $39.8M; cash $961.4M after $555M PIPE","bullets":["Net loss of $39.8M ($0.77 loss per share) vs $42.6M ($1.41 loss per share) in Q2 2023; R&D expense $40.1M.","Cash and cash equivalents $961.4M as of June 30, 2024, up from $526.4M at Dec 31, 2023, after $555M PIPE financing.","Pipeline focused on zelenectide pevedotin (BTC) and BT5528; four abstracts accepted for ESMO 2024.","Jennifer Perry promoted to CSO & head of commercial; Nick Keen transitions to advisor; new Clinical Advisory Board formed.","Repaid $31.9M Hercules loan in July 2024 ahead of maturity; financial runway extended into 2H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086085","json":"https://secwatch.observer/filing/0001104659-24-086085.json","markdown":"https://secwatch.observer/filing/0001104659-24-086085.md","text":"https://secwatch.observer/filing/0001104659-24-086085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924086085/0001104659-24-086085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465924086085/tm2420860d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:21:47.022081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}